Format

Send to

Choose Destination
Ther Adv Med Oncol. 2013 Mar;5(2):133-41. doi: 10.1177/1758834012467661.

Bevacizumab and ovarian cancer.

Author information

1
University of Southern California, Norris Comprehensive Cancer Center, 1441 Eastlake Av., Rm. 3449, Los Angeles, CA 90033, USA.

Abstract

Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that targets vascular endothelial growth factor-A, and is indicated in the treatment of various tumors (colon, lung, renal, and glioblastoma). It has been recently approved for the treatment of ovarian cancer in various countries. This review summarizes the activity and toxicity of bevacizumab in the treatment of ovarian cancer, both as single-agent drug and in combination with cytotoxic chemotherapy. As a single-agent drug, it has shown response rates of 16-21% in the treatment of recurrent ovarian cancer. Two phase III randomized trials have been published evaluating the addition of bevacizumab to standard chemotherapy as front-line treatment of advanced ovarian cancer. In addition, trials evaluating the combination with chemotherapy in recurrent ovarian cancer (platinum-sensitive and platinum-resistant disease) have also been reported. All these trials showed a statistically significant improvement in progression-free survival although no improvement in overall survival has been reported. The main adverse event is hypertension. Other serious, but uncommon adverse events include gastrointestinal perforation as well as renal and central nervous system toxicity.

KEYWORDS:

bevacizumab; combination therapy; ovarian cancer; progression-free survival; single-agent therapy

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center